Novo Biosciences Overview

  • Founded
  • 2012
Founded
  • Status
  • Private
  • Employees
  • 2
Employees
  • Latest Deal Type
  • Seed
  • Latest Deal Amount
  • $4M
Latest Deal Amount
  • Investors
  • 5

Novo Biosciences General Information

Description

Developer of cardiac drugs designed to reverse the life-threatening damage caused by heart attacks. The company's drugs spur the body to heal itself by triggering powerful mechanisms of self-repair and regrowth that lie dormant in genes, enabling patients to regenerate damaged organs and tissues and live a healthier life.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • One City Hall Plaza
  • Ellsworth, ME 04605
  • United States
+1 (207) 000-0000

Novo Biosciences Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Novo Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Seed Round 09-Jun-2020 $4M 00.000 Completed Pre-Clinical Trials
5. Grant 07-Sep-2017 00.000 0000 Completed Pre-Clinical Trials
4. Grant 01-Jan-2017 00.00 0000 Completed Pre-Clinical Trials
3. Accelerator/Incubator 0000 Completed Pre-Clinical Trials
2. Angel (individual) 16-Jul-2015 $75K $75K Completed Pre-Clinical Trials
1. Grant 17-Nov-2014 $25K Completed Pre-Clinical Trials
To view Novo Biosciences’s complete valuation and funding history, request access »

Novo Biosciences Executive Team (3)

Name Title Board Seat Contact Info
Kevin Strange Ph.D Co-Founder, Chief Executive Officer, Chairman & Board Member
Voot Yin Ph.D Co-Founder, Chief Scientific Officer & Board Member
Daniel Coit Advisor
To view Novo Biosciences’s complete executive team members history, request access »

Novo Biosciences Board Members (3)

Name Representing Role Since
Kevin Strange Ph.D Novo Biosciences Co-Founder, Chief Executive Officer, Chairman & Board Member 000 0000
Voot Yin Ph.D Novo Biosciences Co-Founder, Chief Scientific Officer & Board Member 000 0000
You’re viewing 2 of 3 board members. Get the full list »

Novo Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novo Biosciences Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Heart Blood and Lung Institute Government 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
Maine Technology Institute Other 000 0000 000000 0
MDI Biological Laboratory Accelerator/Incubator 000 0000 000000 0
To view Novo Biosciences’s complete investors history, request access »